

# Index

## A

- Acetylcholine system, 64
- Acute fluoxetine treatment, 21
- Adrenocorticotrophic hormone (ACTH), 14
- Agomelatine, 61
- Alzheimer's disease, 489
- Amaryllidaceae
  - chemical composition, 448
  - common names, 447
  - conservation status, 448
  - description, 448
  - ethnomedicinal uses, 449
  - habitat, 448
  - medicinal parts, 448
  - morphology, 448
  - PALOP, 448
  - pharmacological studies, 449
  - world distribution, 448
- Animal models
  - endophenotypes (*see* Endophenotypes)
  - experimental models
    - advantages, 128–130
    - CMS, 127
    - FST, 125–126
    - LH, 123–125
    - olfactory bulbs, 128
    - social stress models, 128
    - TST, 126
  - limitations, 130
  - in rodents, 120
- Annonaceae
  - chemical constituents, 425, 426
  - common names, 425
  - description, 425
  - dosage, 430
  - habitat and world distribution, 425
  - indications and usage, 429
  - medicinal parts, 425
  - morphology, 425
  - pharmacology and bioactivities, 427–429
  - precautions and side effects, 429, 430
- Anthraquinones, 388
- Antidepressants, 48, 56, 58, 367
  - drugs
    - beta-receptor downregulation hypothesis, 46, 47
    - biological and pharmacological activity, 439
    - imipramine, 45
    - iproniazid, 45
    - MAOIs (*see* Monoamine oxidase inhibitors (MAOIs))
    - NA discovery, 44
    - NARIs, 55
    - psychostimulants, 438
    - psychotropic effects, 439
    - receptor-selective (*see* Receptor-selective antidepressant drugs)
    - RIMAS, 52
    - second-generation dual-action antidepressants (*see* Dual action antidepressants)
    - selective serotonin reuptake enhancing antidepressants, 55, 438
    - SSRIs, 53, 54
    - TCAs, 52, 53
    - technological development, 438
    - therapeutic action, 439
    - tricyclic antidepressants, 438

- Antidepressants (*cont.*)
- HPA axis, 65, 66
  - immune system, 66, 67
  - monoamine targets, 63, 64
  - non-monoamine neurotransmitter targets
    - acetylcholine system, 64
    - glutamate system, 65
  - pharmacogenetics, 67, 68
  - search engines, 486
- Anti-fatigue effect, 368
- Apiaceae
- chemical composition, 284, 452
  - common names, 283, 451
  - conservation status, 452
  - description, 451
  - distribution, 451
  - dosage, 287
  - ethnomedicinal uses, 454
  - habitat, 283, 451
  - indications and usage, 287
  - medicinal parts, 284, 452
  - morphology, 284, 451
  - PALOP, 451
  - pharmacological studies, 286, 454, 455
  - photograph, 283
  - precautions and side effects, 287, 455
  - world distribution, 283
- Apocynaceae
- chemical composition, 466, 479
  - common names, 464, 477
  - conservation status, 465, 478
  - description, 465, 477
  - distribution, 465, 477
  - dosage, 480
  - ethnomedicinal uses, 466, 480
  - habitat, 465, 477
  - medicinal parts, 466, 479
  - morphology, 465, 477
  - PALOP, 465, 477
  - pharmacological studies, 466, 480
  - precautions and side effects, 480
- Araceae
- chemical constituents, 293–297
  - common names, 269
  - dosage, 274
  - habitat and world distribution, 270
  - indications and usage, 273
  - in vitro studies, 272
  - in vivo studies, 273
  - medicinal parts, 270
  - morphology, 270
  - photograph, 269
  - precautions and side effects, 273
- Araliaceae, 262, 263, 268, 318, 322, 323
- Eleutherococcus senticosus*
- chemical constituents, 198
  - common names, 196
  - dosage, 205
  - habitat and world distribution, 197
  - indications and usage, 205
  - medicinal parts, 198
  - morphology, 197
  - pharmacology and bioactivities, 203
  - photograph, 197
  - precautions and side effects, 205
  - synonyms, 197
- Oplopanax elatus* (Nakai) Nakai
- anti-convulsant effects, 238
  - chemical constituents, 234
  - common names, 233
  - dosage, 239
  - habitat and world distribution, 234
  - indications and usage, 239
  - medicinal parts, 234
  - morphology, 234
  - pharmacology and bioactivities, 237
  - photograph, 233
  - precautions and side effects, 239
  - synonym, 233
  - species photograph, 262
- Arecaceae, 488, 489
- chemical constituents, 488
  - common names, 487
  - description, 487
  - distribution, 487
  - dosages, 489
  - habitat, 487
  - indications and usage, 489
  - medicinal parts, 488
  - morphology, 487
  - pharmacology and bioactivities
    - in vitro, 488
    - in vivo, 489
  - precautions and side effects, 489
  - stimulatory activity, 489
- Arginine vasopressin (AVP), 14
- Asteraceae
- chemical constituents, 248
  - common names, 247
  - dosage, 256
  - habitat and world distribution, 247
  - indications and usage, 256
  - medicinal parts, 248
  - morphology, 248
  - pharmacology and bioactivities, 255
  - photograph, 247
  - precautions and side effects, 256
  - synonyms, 247

- Astrocytes, 26  
Attention deficit hyperactivity disorder (ADHD), 393  
Atypical antipsychotics, 64  
Australian Aborigine smoking ceremonies, 485
- B**  
*Bacopa monnieri* (L.) Pennell, 442–446  
Beta-receptor downregulation hypothesis, 46, 47, 55  
BIOSIS databases, 154  
Bipolar disorder  
  bipolar I disorder, 3  
  bipolar II disorder, 4  
  cyclothymic disorder, 4  
  hypomanic episode, 4  
  other related disorder, 4  
  substance/medication-induced bipolar disorder, 4  
Blood–brain barrier (BBB), 540  
*Boophone disticha*, 447  
Brain-derived neurotrophic factor (BDNF), 20, 21, 46  
Brodmann's 25 area, 23  
Bupropion, 47, 58  
Burning mouth syndrome, 393  
BV2 microglial culture, 100–101
- C**  
C6 glioma cell line, 99–100  
Catecholamine hypothesis, 55  
CB1 cannabinoid receptor-deficient mice, 562  
*Centella asiatica* (L.), 452  
Cheese reaction, 50  
China National Knowledge Infrastructure (CNKI), 184  
Chinese herbal medicine (CHM)  
  antidepressant targets and mechanisms, 260  
  Apiaceae  
    chemical constituents, 284  
    common names, 283  
    dosage, 287  
    habitat and world distribution, 283  
    indications and usage, 287  
    in vitro studies, 286  
    in vivo studies, 286  
    medicinal parts, 284  
    morphology, 284  
    photograph, 283  
    precautions and side effects, 287  
  Araceae  
    chemical constituents, 293–297  
    common names, 269  
    dosage, 274  
    habitat and world distribution, 270  
    indications and usage, 273  
    in vitro studies, 272  
    in vivo studies, 273  
    medicinal parts, 270  
    morphology, 270  
    photograph, 269  
    precautions and side effects, 273  
  Araliaceae  
    chemical constituents, 263, 319  
    common names, 262, 318  
    dosage, 268, 323  
    external use, 268  
    habitat and world distribution, 262, 318  
    indications and usage, 268, 322  
    in vitro studies, 322  
    in vivo studies, 268, 322  
    medicinal parts, 263, 319  
    morphology, 263, 318  
    pharmacology and bioactivities, 268  
    photograph, 318  
    precautions and side effects, 268, 323  
    species photograph, 262  
  complementary and alternative medicine, 260  
  complex multicomponent mixtures, 260  
  Crassulaceae  
    chemical constituents, 366  
    common names, 365  
    dosage, 368  
    habitat and world distribution, 365  
    indications and usage, 368  
    in vitro studies, 367  
    in vivo studies, 367  
    medicinal parts, 366  
    morphology, 365  
    photograph, 365  
    precautions and side effects, 368  
  Cyperaceae  
    common names, 298  
    dosage, 307  
    habitat and world distribution, 299  
    indications and usage, 307  
    in vitro studies, 306  
    in vivo studies, 307  
    morphology, 299  
    photograph, 298  
    precautions and side effects, 307  
  Ginkgoaceae  
    chemical constituents, 315  
    common names, 314  
    dosage, 317  
    habitat and world distribution, 314

- Chinese herbal medicine (CHM) (*cont.*)  
indications and usage, 317  
in vitro studies, 317  
in vivo studies, 317  
medicinal parts, 315  
morphology, 314  
photograph, 314  
precautions and side effects, 317
- Guttiferae  
chemical constituents, 325  
common names, 324  
dosage, 327  
habitat and world distribution, 324  
indications and usage, 327  
in vitro studies, 326  
in vivo studies, 326  
medicinal parts, 325  
morphology, 324, 325  
photograph, 324  
precautions and side effects, 327
- Iridaceae  
chemical constituents, 293–297  
common names, 292  
dosage, 297  
habitat and world distribution, 292  
indications and usage, 297  
in vitro studies, 297  
in vivo studies, 297  
medicinal parts, 293  
morphology, 293  
photograph, 292  
precautions and side effects, 297
- Liliaceae  
chemical constituents, 276–279, 281  
common names, 275, 280  
dosage, 279, 283  
habitat and world distribution, 275, 280  
indications and usage, 279, 282  
in vitro studies, 279, 282  
in vivo studies, 279, 282  
medicinal parts, 276, 281  
morphology, 275, 280  
photograph, 275, 280  
precautions and side effects, 279, 282
- Nymphaeaceae  
chemical constituents, 329  
common names, 328  
dosage, 332  
habitat and world distribution, 328  
indications and usage, 331  
in vitro studies, 331  
in vivo studies, 331  
medicinal parts, 329  
morphology, 328  
photograph, 328  
precautions and side effects, 332
- Papaveraceae  
common names, 288  
dosage, 291  
habitat and world distribution, 288  
indications and usage, 291  
in vivo studies, 291  
in vitro studies, 290  
medicinal parts, 289  
morphology, 288  
photograph, 288  
precautions and side effects, 291
- Polygalaceae  
chemical constituents, 339  
common names, 338  
dosage, 342  
habitat and world distribution, 338  
indications and usage, 342  
in vitro studies, 341  
in vivo studies, 341  
medicinal parts, 339  
morphology, 338  
photograph, 338  
precautions and side effects, 342
- Polygonales  
chemical constituents, 344  
common names, 342  
habitat and world distribution, 343  
indications and usage, 345  
in vitro studies, 345  
in vivo studies, 345  
medicinal parts, 344  
morphology, 343  
photograph, 342  
precautions and side effects, 345
- Ranunculaceae  
chemical constituents, 333  
common names, 332  
dosage, 337  
habitat and world distribution, 332  
indications and usage, 337  
in vitro studies, 336  
in vivo studies, 336  
medicinal parts, 333  
morphology, 333  
photograph, 332  
precautions and side effects, 337
- Rhamnaceae  
chemical constituents, 375  
common names, 374  
dosage, 378  
habitat and world distribution, 375  
indications and usage, 378

- medicinal parts, 375
- morphology, 375
- pharmacology and bioactivities, 378
- photograph, 374
- precautions and side effects, 378
- Rutaceae
  - chemical constituents, 309–313
  - common names, 308
  - dosage, 313
  - habitat and world distribution, 308
  - indications and usage, 313
  - medicinal parts, 309
  - morphology, 308
  - pharmacology and bioactivities, 313
  - photograph, 308
  - precautions and side effects, 313
- Umbelliferae
  - chemical constituents, 347
  - common names, 346
  - dosage, 351
  - habitat and world distribution, 346
  - indications and usage, 350
  - medicinal parts, 347
  - morphology, 346
  - photograph, 346
  - precautions and side effects, 351
- Valerianaceae
  - chemical constituents, 370
  - common names, 369
  - dosage, 373
  - habitat and world distribution, 369
  - indications and usage, 373
  - in vitro studies, 372
  - in vivo studies, 372
  - medicinal parts, 370
  - morphology, 370
  - photograph, 369
  - precautions and side effects, 373
- Zingiberaceae
  - chemical constituents, 359
  - common names, 358
  - dosage, 364
  - habitat and world distribution, 358
  - indications and usage, 364
  - in vitro studies, 363
  - in vivo studies, 363, 364
  - medicinal parts, 359
  - morphology, 358
  - photograph, 358
  - precautions and side effects, 364
- Chronic electroconvulsive seizure (ECS)
  - treatment, 20
- Chronic electroconvulsive shock, 21
- Chronic mild stress (CMS), 127–128
- Chronic stress models, 123
- Circadian rhythm, 30–31
- Cissampelos mucronata* A, 457
- Cochrane Library, 154
- Combretaceae, 520–522, 525, 526
- Commelinaceae
  - chemical composition, 469
  - common names, 467
  - conservation status, 468
  - description, 467
  - distribution, 467
  - ethnomedicinal uses, 469
  - habitat, 467
  - medicinal parts, 468
  - morphology, 468
  - PALOP, 467
  - pharmacological studies, 470
- Complementary and alternative medicine (CAM)
  - Hypericum perforatum* L. (see Hypericaceae)
  - Melissa officinalis* L. (see Lamiaceae)
  - Ocimum basilicum* L. (see Lamiaceae)
  - Tilia* sp. (see Malvaceae/Tiliaceae)
  - Valeriana officinalis* L. (see Valerianaceae)
  - Verbena officinalis* L. (see Verbenaceae)
- Congenital learned helpless (cLH) line, 562
- Corticotropin-releasing factor (CRF), 14
- Corticotropin-releasing hormone (CRH), 14
- Crassulaceae
  - chemical constituents, 366
  - common names, 365
  - dosage, 368
  - habitat and world distribution, 365
  - indications and usage, 368
  - in vitro studies, 367
  - in vivo studies, 367
  - medicinal parts, 366
  - morphology, 365
  - photograph, 365
  - precautions and side effects, 368
- Cyclothymic disorder, 4
- Cyperaceae
  - chemical constituents, 300–306
  - common names, 298
  - dosage, 307
  - habitat and world distribution, 299
  - indications and usage, 307
  - in vitro studies, 306
  - in vivo studies, 307
  - medicinal parts, 300
  - morphology, 299, 300
  - photograph, 298
  - precautions and side effects, 307
- Cytochrome P450 (CYP) enzymes, 563
- Cytokine theory, 17, 18

**D**

Dentate gyrus (DG), 18

Depressive disorders

- antidepressant drugs and medicinal plants, 438–440
- DMDD, 2
- economic burden
  - Australia, 11
  - China, 11
  - Colombia, 12
  - Europe, 11
  - South Africa, 11
  - United States, 11
- major depressive disorder, 2
- mental illness, 438
- monoamine theories (*see* Monoamine oxidase inhibitors (MAOIs), theories)
- other medical conditions, 3
- persistent depressive disorder (dysthymia), 2
- pharmacological activities, 438
- premenstrual dysphoric disorder (dysthymia), 2
- prevalence, 4
- risk of recurrence, 44
- substance/medication-induced depressive disorder, 3

Desipramine treatment, 21

Desmethylvenlafaxine (*O*-desmethylvenlafaxine), 56

Dexamethasone (DEX), 15

Diagnostic and Statistical Manual of Mental Disorders (DSM-5), 1

Diagnostic and Statistical Manual of Mental Disorders (DSM-IV), 123

Disability-adjusted life years (DALYs), 5

Disruptive mood dysregulation disorder (DMDD), 2

Drug delivery system

- agomelatine, 559
- amitriptyline, 558
- antidepressant drugs, 560, 561
- bioavailability, 560
- bupropion, 558
- citalopram, 558
- duloxetine, 558
- escitalopram, 558
- fluoxetine, 558
- imipramine, 558
- iproniazid, 557
- irreversible and nonselective monoamine oxidase inhibitors, 557
- ketamine, 559
- mirtazapine, 559
- moclobemide, 558

- nanotechnology-based products, 560
- phenelzine, 557
- reboxetine, 558
- selegiline, 560
- tianeptine, 559
- tranylcypromine, 558
- venlafaxine, 558
- vilazodone, 558
- zimelidine, 558

Dual action antidepressants

- noradrenaline and dopamine reuptake inhibitors, 58
- SNRIs, 56
  - desmethylvenlafaxine (*O*-desmethylvenlafaxine), 56
  - duloxetine, 57
  - milnacipran, 57
  - venlafaxine, 56

Dulbecco's modified Eagle's medium (DMEM), 83

Duloxetine, 57

**E**

EMBASE, 154

Endophenotypes

- anhedonia, 121
- anxiety, 122
- appetite/weight gain, 121
- behavioral distress, 121
- neuroendocrine disorders, 121
- sleep architecture, alterations, 121

Epigenetic theory, 27–30

Espacenet patent databases, 184

Establishing Moderators/Mediators for a Biosignature of Antidepressant Response in Clinical Care (EMBARC), 68

Ethnomedicine, 436

Europe PubMed Central, 137

Excitatory amino acid transporters (EAATs), 22

**F**

Fabaceae

- chemical composition, 462
- common names, 460
- conservation status, 462
- description, 460
- distribution, 460
- dosage, 463
- ethnomedicinal uses, 462
- habitat, 460
- medicinal parts, 462

morphology, 460  
 PALOP, 460  
 pharmacological studies, 463  
 precautions and side effects, 463  
 Fetal mesencephalic neural stem cells  
 (fmNSCs), 83  
 Fibroblast growth factor 2 (FGF2), 77  
 Fibroblast growth factor receptor (FGFR), 85  
 Forced swim test (FST), 125–126, 204

## G

GABAergic hypothesis, 24–26  
 $\gamma$ -aminobutyric acid (GABA), 24  
*Gelidium amansii* J.V. Lamouroux, 82  
 Ginkgoaceae  
 chemical constituents, 315  
 common names, 314  
 dosage, 317  
 habitat and world distribution, 314  
 indications and usage, 317  
 in vitro studies, 317  
 in vivo studies, 317  
 medicinal parts, 315  
 morphology, 314  
 photograph, 314  
 precautions and side effects, 317  
 Glia-derived neurotrophic factor (GDNF), 77  
 Glial cell cultures, 17  
 BV2 microglial culture, 100  
 depression, 101  
 methodology, 101  
 pathology, 26–27  
 primary  
 depression in, 97–99  
 methodology, 96, 97  
 rat C6 glioma cell line  
 depression, 99, 100  
 methodology, 99  
 Glial fibrillary acidic protein (GFAP), 27  
 Global burden of disease (GBD), 5  
 Glucocorticoid receptor (GR), 15  
 Glutamate-based depression, 23  
 Glutamate hypothesis, 21–24  
 Glutamate system, 65  
 Glycogen synthase kinase-3 beta (GSK3 $\beta$ ), 559  
 Google Scholar, 137, 439, 486  
 Grave's disease and nystagmus, 500  
*Griffonia simplicifolia*, 461  
 Guttiferae  
 chemical constituents, 325  
 common names, 324  
 dosage, 327  
 habitat and world distribution, 324

indications and usage, 327  
 in vitro studies, 326  
 in vivo studies, 326  
 medicinal parts, 325  
 morphology, 324, 325  
 photograph, 324  
 precautions and side effects, 327

## H

Herbal antidepressants  
 BBB, 540  
 diagnosis and management, 530–531  
 epidemiology, 530  
 FDA regulations  
 analytical procedures, 551  
 dietary products, 549, 550  
 low-quality product, 549  
 producers/manufacturers and sellers, 549  
 quality control and standardisation, 550  
 intranasal delivery, 547  
 mechanisms  
 monoamine, 536  
 mood-elevating effects, 536  
 neurotrophic hypothesis, 537  
 phytochemicals, 537  
 side effects, reduction, 536  
 nanodevices  
 genetic abnormalities, 545  
 nanoscaled implants, 546  
 nanosensors, 546  
 nanowires, 546  
 neural nano-repairs, 546  
 novel herbal drug carriers  
 carrier-mediated transport, 541  
 characteristics, 541  
 endothelial cells, 542  
 gold nanoparticles, 545  
 herbal compounds, 541  
 in vivo activity, 540  
 liposomes, 543  
 lutein, 541  
 nanocarriers, 542  
 NLCs, 544, 545  
 polymeric nanoparticles, 544  
 silver nanoparticles, 545  
 SLNs, 542  
 SMEDDS, 542  
 transport/carriers, 541  
 oxidant-antioxidant balance, 535, 536  
 polyphenols, 531, 532, 535  
 risk factors, 548  
 targeted drugs, 537–538  
 transdermal delivery, 547, 548

- High anxiety-related behavior (HAB) rats, 562
- Histone acetylation, 28
- Histone methylation, 30
- Human genome, 562–563
- 5-Hydroxytryptamine transporter-linked polymorphic promoter region (5-HTTLPR), 68
- Hyperforin, 82
- Hypericaceae, 390, 391
  - chemical constituents, 140, 186, 388
  - CNS-related activities, 191
  - common names, 139, 184, 387
  - description, 387
  - dosage, 145, 193, 392, 393
  - habitat and world distribution, 139, 185, 387
  - indications and usage, 144, 192, 391
  - in vitro, 142, 191, 390
  - in vivo, 143, 191, 391
  - medicinal part, 140, 186, 388
  - morphology, 139, 185, 387
  - photograph, 139, 185
  - precautions and side effects, 144, 192
  - side effects and warnings, 392
  - synonyms, 185
- Hypericin, 82
- Hypericum perforatum* L., 83
- Hypomanic episode, 4
- Hypothalamic-pituitary-adrenal (HPA) axis, 14, 16, 65, 66, 77
- Hypothesis, depression
  - epigenetic mechanisms, 78
  - of glial cells, 78
  - glutamatergic of, 77
  - HPA axis, 77
  - neuroinflammatory hypothesis, 77
  - neurotrophic hypothesis, 77
  - oldest, 76
- I**
- Icariin, 81
- Imipramine, 45
- Inflammation and cancer, 525
- Inhibitory postsynaptic currents (IPSCs), 24
- Iproniazid, 45, 49
- Iridaceae
  - chemical constituents, 293–297
  - common names, 292
  - dosage, 297
  - habitat and world distribution, 292
  - indications and usage, 297
  - in vitro studies, 297
  - in vivo studies, 297
  - medicinal parts, 293
  - morphology, 293
  - photograph, 292
  - precautions and side effects, 297
- K**
- Kai-Xin-San, 82, 85
- L**
- Lamiaceae
  - Leonurus cardiaca* L.
    - chemical constituents, 208
    - common names, 207
    - dosage, 216
    - habitat and world distribution, 207
    - indications and usage, 215
    - medicinal part, 207
    - morphology, 207
    - pharmacology and bioactivities, 213
    - photograph, 207
    - precautions and side effects, 215
    - synonyms, 207
  - Leonurus turkestanicus*
    - chemical constituents, 220
    - common names, 219
    - habitat and world distribution, 219
    - indications and usage, 223
    - medicinal parts, 220
    - morphology, 219
    - pharmacology and bioactivities, 222
    - photograph, 219
    - precautions and side effects, 223
    - synonyms, 219
  - Melissa officinalis* L.
    - chemical constituents, 163
    - common names, 162
    - dosage, 168
    - habitat and world distribution, 163
    - indications and usage, 167
    - medicinal parts, 163
    - morphology, 163
    - pharmacology and bioactivities, 167
    - photograph, 163
    - precautions and side effects, 167
  - Nepeta cataria* L.
    - chemical constituents, 225
    - common names, 224
    - dosage, 230
    - habitat and world distribution, 225
    - indications and usage, 230
    - medicinal parts, 225
    - morphology, 225



- pharmacology and bioactivities, 229
  - photograph, 224
  - precautions and side effects, 230
  - synonyms, 224
- Ocimum basilicum* L.
  - chemical constituents, 157
  - common names, 156
  - dosage, 161
  - habitat and world distribution, 156
  - indications and usage, 161
  - medicinal parts, 157
  - morphology, 157
  - pharmacology and bioactivities, 160
  - photograph, 156
  - precautions and side effects, 161
- Learned helplessness (LH), 123–125
- Libellus de Medicinalibus*, 382
- Liliaceae
  - chemical constituents, 276–279, 281
  - common names, 275, 280
  - dosage, 279, 283
  - habitat and world distribution, 275, 280
  - indications and usage, 279, 282
  - in vitro studies, 279, 282
  - in vivo studies, 279, 282
  - medicinal parts, 276, 281
  - morphology, 275, 280
  - photograph, 275, 280
  - precautions and side effects, 279, 282
- Lophophora williamsii*, 385
- Lymphocytes, 16
  
- M**
- Macrophages, 16
- Magnoliaceae
  - chemical constituents, 396
  - common names, 395
  - description, 395
  - dosage, 398
  - habitat and world distribution, 395
  - indications and usage, 397
  - medicinal parts, 396
  - morphology, 395
  - pharmacology and bioactivities, 396
  - precautions and side effects, 397
- Major depressive disorder, 2
- Malpighiaceae
  - chemical constituents, 420
  - common names, 420
  - description, 420
  - dosage
    - external use, 423
    - internal use, 423
  - habitat and world distribution, 420
  - indications and usage, 422
  - medicinal parts, 420
  - morphology, 420
  - pharmacology and bioactivities, 421, 422
  - precautions and side effects, 423
- Malvaceae/Tiliaceae
  - chemical constituents, 169
  - common names, 168
  - dosage, 176
  - habitat and world distribution, 168
  - indications and usage, 176
  - medicinal parts, 169
  - morphology, 169
  - pharmacology and bioactivities, 175
  - photograph, 168
  - precautions and side effects, 176
- Maprotiline, 46
- Medicinal plants
  - Aztecs, 382
  - electronic databases, 439
  - ethnomedicinal data, 439
  - IMEPLAM, 384
  - mental diseases, 383
  - phytochemical constituents, 440
  - psychotropic substances, 384
- Melancholia, 44
- Melissae aetheroleum*, 166
- Menispermaceae
  - chemical composition, 457
  - common names, 456
  - conservation status, 457
  - description, 456
  - distribution, 456
  - ethnomedicinal uses, 458
  - habitat, 456
  - medicinal parts, 457
  - morphology, 456, 457
  - PALOP, 456
  - pharmacological studies, 459
- Mianserin, 59
- Microglia, 16, 26
- MicroRNAs (miRNAs), 30
- Milnacipran, 57
- Mineralocorticoid receptor (MR), 15
- Mirtazapine, 59
- Mondia whitei*, 465
- Monoamine hypothesis of depression, 45
- Monoamine oxidase inhibitors (MAOIs),
  - 46, 48
  - atypical antipsychotics, 64
  - irreversible binding, 51
  - nonselective binding, 49, 50
  - SSRIs, 51

- Monoamine oxidase inhibitors (MAOIs) (*cont.*)  
 theories  
   golden decade of psychopharmacology, 12  
   iproniazid, 12  
   MAOIs, 12  
   noradrenaline hypothesis, 13  
   reserpine, 13  
   serotonin hypothesis, 13  
   SSRIs, 14  
   triple monoamine reuptake inhibitors, 63
- Monocytes, 16
- Moringa oleifera* Lam, 82
- Myrtaceae  
 chemical constituents, 492  
 common names, 491  
 description, 491  
 distribution, 491  
 dosage  
   external use, 493  
   internal use, 493  
 habitat, 491  
 indications and usage, 492  
 medicinal parts, 492  
 morphology, 491  
 pharmacology and bioactivities  
   in vitro, 492  
   in vivo, 492  
 precautions and side effects, 493
- N**
- Nanostructured lipid carriers (NLCs), 544, 545
- Nefazodone, 60
- Nelumbonaceae  
 antidepressant activity, 504  
 chemical constituents, 502  
 common names, 501  
 description, 501  
 dosage, 504  
 habitat and world distribution, 501  
 medicinal parts, 502  
 morphology, 501  
 pharmacology and bioactivities, 503  
 precautions and side effect, 504
- Neurogenesis, 18–20, 78, 81, 83, 88
- Neuroinflammation, 16–18
- Neuronal cell models  
 AR-5 cell line, 94  
   depression, 95  
   methodology, 95  
 HT-22 cell  
   depression in, 94  
   methodology, 93
- PC12 cell line  
   depression in, 84, 85, 87  
   methodology, 83, 84  
 primary neuronal cell cultures  
   depression studies in, 81–83  
   methodology, 79–81  
 SH-SY5Y cells, 91  
   depression in, 92, 93  
   methodology, 92
- Neuroplasticity, 20, 78, 95, 98, 100, 102
- Neurotrophic theory, 20–21
- N*-methyl-D-aspartate (NMDA) receptors, 23
- Non-rapid eye movement (NREM), 31
- Noradrenaline (NA), 44, 45
- Noradrenaline Reuptake Inhibitors (NARIs), 46, 55
- Noradrenergic and specific serotonergic antidepressants (NASSAs), 59–60
- Novel drug delivery systems (NDDS), 538
- Nymphaeaceae  
 chemical constituents, 329  
 common names, 328  
 dosage, 332  
 habitat and world distribution, 328  
 indications and usage, 331  
 in vitro studies, 331  
 in vivo studies, 331  
 medicinal parts, 329  
 morphology, 328  
 photograph, 328  
 precautions and side effects, 332
- O**
- Oceania  
 climatic and environmental conditions, 485  
 physical and psychological complaints, 485  
 plant-based medicinal system, 485  
 plant-based treatments, 486  
 Straits of Malacca, 484
- Oligodendrocytes, 26
- P**
- Palisota hirsuta*, 468
- Papaveraceae  
 chemical constituents, 289  
 common names, 288  
 dosage, 291  
 habitat and world distribution, 288  
 indications and usage, 291  
 in vivo studies, 291  
 in vitro studies, 290  
 medicinal parts, 289

- morphology, 288
  - photograph, 288
  - precautions and side effects, 291
  - Paraventricular nucleus (PVN), 14
  - Passifloraceae
    - chemical constituents, 401
    - common names, 399
    - description, 399
    - dosage
      - external use, 404
      - internal use, 404
    - habitat and world distribution, 399, 400
    - indications and usage, 404
    - medicinal parts, 401
    - morphology, 400
    - pharmacology and bioactivities, 402, 403
    - precautions and warnings, 404
  - Passiflora incarnata* L., 83
  - Persistent depressive disorder (dysthymia), 2
  - Personalized medicine
    - bipolar disorder, 559
    - clinical trials, 563
    - dysthymia, 564
    - lithium, 559
  - P-glycoprotein, 68
  - Pharmacogenomics
    - biological therapies, 560
    - lamotrigine, 559
    - personalized antidepressant treatments, 563
  - Piperaceae
    - chemical constituents, 507
    - common names, 506
    - description, 506
    - dosage, 509
    - habitat and world distribution, 506
    - hypnotic and sedative, 509
    - medicinal parts, 507
    - morphology, 506
    - pharmacology and bioactivities
      - in vitro, 508
      - in vivo, 509
    - Piper hederaceum*, 511–513
    - precautions and side effects, 509
    - treatment of Parkinson's disease, 509
  - Piper methysticum* G., 536
  - Polygalaceae
    - chemical composition, 339, 473
    - common names, 338, 471
    - conservation status, 473
    - description, 472
    - distribution, 472
    - dosage, 342
    - ethnomedicinal uses, 475
    - habitat, 338, 472
    - indications and usage, 342
    - in vitro studies, 341
    - in vivo studies, 341
    - medicinal parts, 339, 473
    - morphology, 338, 472
    - PALOP, 472
    - pharmacological studies, 475, 476
    - photograph, 338
    - precautions and side effects, 342
    - world distribution, 338
  - Polygonales
    - chemical constituents, 344
    - common names, 342
    - habitat and world distribution, 343
    - indications and usage, 345
    - in vitro studies, 345
    - in vivo studies, 345
    - medicinal parts, 344
    - morphology, 343
    - photograph, 342
    - precautions and side effects, 345
  - Polynesia, 485
  - Portuguese-speaking African countries (PALOP)
    - African traditional medicine, 436, 437
    - cultural and ethnical diversity, 434
    - geographical location, 435
    - health services, 435
  - Premenstrual dysphoric disorder, 2
  - Primary glial cell cultures, 96–99
  - PubMed, 137, 184, 439, 486
- R**
- Ranunculaceae
    - chemical constituents, 333
    - common names, 332
    - dosage, 337
    - habitat and world distribution, 332
    - indications and usage, 337
    - in vitro studies, 336
    - in vivo studies, 336
    - medicinal parts, 333
    - morphology, 333
    - photograph, 332
    - precautions and side effects, 337
  - Rapid eye movement (REM) sleep, 31
  - Reboxetine, 46, 55
  - Receptor-selective antidepressant drugs
    - dual-action selective serotonergic antidepressants, 60
      - vilazodone, 61
      - vortioxetine, 61
    - melatonin receptor-selective drugs, 61

- Receptor-selective antidepressant drugs (*cont.*)
- NASSAs
    - mianserin, 59
    - mirtazapine, 59
    - nefazodone, 60
    - trazodone, 59, 60
  - Research Domain Criteria (RDoC) project, 68
  - Reversible selective monoamine oxidase inhibitors (RIMAs), 52
  - Rhamnaceae
    - chemical constituents, 375
    - common names, 374
    - dosage, 378
    - habitat and world distribution, 375
    - indications and usage, 378
    - medicinal parts, 375
    - morphology, 375
    - pharmacology and bioactivities, 378
    - photograph, 374
    - precautions and side effects, 378
  - Rutaceae
    - chemical constituents, 309–313
    - common names, 308
    - dosage, 313
    - habitat and world distribution, 308
    - indications and usage, 313
    - medicinal parts, 309
    - morphology, 308
    - pharmacology and bioactivities, 313
    - photograph, 308
    - precautions and side effects, 313
- S**
- SciELO, 439
  - ScienceDirect, 439
  - SciFinder, 184
  - Scopus, 184, 439, 486
  - Scrophulariaceae
    - chemical composition, 443
    - common names, 442
    - description, 443
    - dosage, 446
    - ethnomedicinal uses, 445
    - habitat, 443
    - medicinal parts, 443
    - morphology, 443
    - PALOP distribution, 443
    - pharmacology and bioactivities, 445
    - precautions and side effects, 445
    - world distribution, 443
  - Seasonal affective disorder (SAD), 31
  - Securidaca longipedunculata*, 472
  - Selective serotonin reuptake inhibitors (SSRIs), 46, 51, 53, 54
  - Selegiline (Deprenyl), 50
  - Self-microemulsifying drug delivery system (SMEDDS), 542
  - Serotonin (5-HT), 45, 51
  - Serotonin transporter (SERT) binding agent, 137
  - Solanaceae
    - Duboisia hopwoodii*
      - anaesthetic, 496
      - chemical constituents, 495
      - common names, 494
      - description, 494
      - dosage, 496
      - habitat and world distribution, 494
      - indications and usage
      - medicinal parts, 495
      - morphology, 494
      - pharmacology and bioactivities, 496
      - precautions and side effects, 496
      - stimulant, 496
    - Duboisia myoporoides*
      - chemical constituents, 498, 499
      - common names, 497
      - description, 497
      - dosage, 500
      - habitat and world distribution, 497
      - indications and usage, 499
      - in vitro, 499
      - in vivo, 499
      - medicinal parts, 498
      - morphology, 498
      - ophthalmology, 500
      - Parkinson's disease, 500
      - pharmacology and bioactivities
      - precautions and side effects, 500
      - sedative and hypnotic, 499
  - Solid Lipid Nanoparticles (SLNs), 542
  - Subgranular zone (SGZ), 18
  - Substance/medication-induced bipolar disorder, 4
  - Substance/medication-induced depressive disorder, 3
  - Subventricular zone (SVZ), 18
  - Suprachiasmatic nucleus (SCN), 30, 31
- T**
- Tail suspension tests (TST), 126–127, 204
  - Tiliaceae, 410
    - chemical constituents, 407
    - common names, 406
    - description, 406
    - dosage
      - external use, 410
      - internal use, 410

- habitat and world distribution, 406
- indications and usage, 409
- medicinal parts, 407
- morphology, 407
- pharmacology and bioactivities, 408, 409
- precautions and warnings, 409

Toxline, 184

Traditional chinese medicine (TCM), 261

Transdermal drug delivery system (TDDS), 548

Tranylcypromine, 21

Trazodone, 59, 60

Tricyclic antidepressant drugs (TCAs), 52, 53

Triple monoamine reuptake inhibitors, 63, 64

Tyramine, 50

## U

Umbelliferae

- chemical constituents, 347
- common names, 346
- dosage, 351
- habitat and world distribution, 346
- indications and usage, 350
- medicinal parts, 347
- morphology, 346
- pharmacology and bioactivities, 350
- photograph, 346
- precautions and side effects, 351
- Rhizoma Chuanxiong*, 352, 353, 357

Unpredictable chronic mild stress (UCMS), 562

## V

Valerianaceae

- chemical constituents, 147, 242, 370, 412
- common names, 146, 240, 369, 411
- description, 411
- dosage, 155, 245, 373, 416, 417
- habitat and world distribution, 146, 241, 369, 411
- indications and usage, 154, 245, 373, 415
- in vitro studies, 152, 372
- in vivo studies, 153, 372
- medicinal parts, 147, 242, 370, 412
- morphology, 147, 241, 370, 411
- pharmacology and bioactivities, 243, 413–415
- photograph, 146, 241, 369
- precautions and side effects, 154, 245, 373, 416
- synonyms, 241

*Valeriana officinalis* L., 83

Valproic acid, 559

Vascular endothelial growth factor (VEGF), 77

Venlafaxine, 56

Ventral tegmental area (VTA), 21

Verbenaceae

- chemical constituents, 178
- common names, 177
- dosage, 181
- habitat and world distribution, 178
- medicinal parts, 178
- morphology, 178
- pharmacology and bioactivities, 180
- photograph, 178
- precautions and side effects, 181

Vesicular Glu transporters (VGLUTs), 22

Vilazodone, 61

Vortioxetine, 61

## W

Web of Science, 184, 439

Winteraceae

- antiseptic properties, 518
- chemical constituents, 516
- common names, 515
- description, 515
- dosage, 519
- habitat and world distribution, 515
- medicinal parts, 515
- morphology, 515
- pharmacology and bioactivities, 517, 518
- precautions and side effects, 518
- sedative and hypnotic, 518
- stimulant, 518
- treatment of Parkinson's disease, 518

## X

*Xysmalobium undulatum* (L.), 478

## Y

Years lived with disability (YLD), 5

## Z

Zingiberaceae

- chemical constituents, 359
- common names, 358
- dosage, 364
- habitat and world distribution, 358
- in vitro studies, 363
- in vivo studies, 363, 364
- medicinal parts, 359
- morphology, 358
- photograph, 358
- precautions and side effects, 364